

IN THE SPECIFICATION:

Please cancel the four line amendment to the specification filed January 7, 1994 at page 11, line 15 and replace it with the following (revised) amendment.

B1
--Hybridoma F80-1B9-F12 was deposited with ATCC on May 11, 1993 and given ATCC designation HB11344.--

B2
--At page 6, line 23, after "A8" insert --monoclonal antibody from the hybridoma deposited with the ATCC on May 11, 1993 and assigned ATCC designation HB 11344.--

IN THE CLAIMS:

In claim 1, line 2, after the word "bind", insert --specifically--.

REMARKS

AMENDMENT TO SPECIFICATION: The prior amendment to the specification has been canceled and replaced with a revised amendment which avoids a new matter objection. Page 6 is amended to show the ATCC deposit of the "A8" hybridoma. Enclosed is a Declaration under 37 CFR 1.132 by co-inventor G. Wetzel pointing out that the cell line earlier objected to as new matter (F448-1D1-A8) is in fact the hybridoma that expressed the "A-8" monoclonal cited at page 6, line 23 and that "A-8" is simply a shorthand designation for "F448-1D1-A8" which has in fact been deposited with ATCC.